ReviewGut pathogens2025
Machine learning approach and internet of things technologies to unravel the complex interaction between microbiome-metabolome in inflammatory bowel disease: a new frontier in precision medicine.
Review in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine Learning for Colitis-Associated Cancer in Inflammatory Bowel Disease: Evidence and Future Directions Toward Precision Medicine, a Narrative Review.International journal of molecular sciences · 2026Review
- From algorithms to clinical execution: A cross-validated knowledge atlas of AI-enabled precision care (2015-2025).Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Inflammatory bowel diseases (IBD) are chronic, relapsing inflammatory disorders with ulcerative colitis (UC) and Crohns disease (CD) representing the two major phenotypes. While these conditions share common features, they exhibit distinct clinical presentations, disease behaviors, and pathogenetic mechanisms, highlighting the complexity of IBD. The global incidence and prevalence of IBD have risen dramatically in recent decades, probably linked to environmental changes such as dietary habits, urbanization, and reduced microbial exposure during early life, highlighting the interplay between environmental and genetic factors in disease pathogenesis. However, genetic factors alone cannot fully explain disease onset, emphasizing the critical role of environmental and microbial influences. Dysbiosis, characterized by reduced microbial diversity, loss of beneficial commensals, and an overabundance of pathogenic taxa, has emerged as a hallmark of IBD. Recent research has increasingly focused on the functional consequences of dysbiosis, its impact on microbial metabolites and pathways that contribute to chronic inflammation and disease progression. Understanding the functional implications of multi-omics changes, rather than simply cataloguing compositional changes, is now a priority in IBD research. Using artificial intelligence to combine data from noninvasive multi-omics technologies offers a significant opportunity to explore interactions among individual omics. It could represent a shift in IBD research by showing the complex mechanisms behind disease. This approach may revolutionize diagnostics and treatments, improving the quality of life for patients through precision medicine. This review aims to provide a comprehensive assessment of current progress. It highlights critical challenges and suggests possible future directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.